Blood protein may reveal who benefits from liver cancer immunotherapy

This study is for adults with advanced liver cancer who are starting a common immunotherapy combination (Atezolizumab and Bevacizumab). Researchers want to see if levels of a protein called Glypican-3 in the blood can help predict how well the treatment works. About 240 participants will have their blood tested before treatment, at 3 weeks, and at 3 months. The goal is to find a simple way to identify which patients are most likely to benefit from this therapy.